{"id":742175,"date":"2012-10-23T13:15:00","date_gmt":"2012-10-23T13:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/"},"modified":"2023-03-22T00:04:21","modified_gmt":"2023-03-22T04:04:21","slug":"merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/","title":{"rendered":"Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation"},"content":{"rendered":"<p class=\"bwalignc\">       New Phase III Study Presented at the Annual Meeting of the American        Society for Reproductive Medicine     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced results from the PURSUE Phase III study of 1,390 women,<br \/>\n      aged 35-42 years, for corifollitropin alfa, the company&#8217;s<br \/>\n      investigational fertility treatment for controlled ovarian stimulation<br \/>\n      in women participating in vitro fertilization (IVF) or intracytoplasmic<br \/>\n      sperm injection (ICSI). The study met its primary endpoint of achieving<br \/>\n      vital pregnancy rates with data revealing that a single injection of 150<br \/>\n      mcg of corifollitropin alfa was non-inferior to seven daily injections<br \/>\n      of 300 IU recombinant follicle stimulating hormone (rFSH). The study<br \/>\n      also evaluated key secondary endpoints of ongoing pregnancy rates and<br \/>\n      the number of oocytes (the female reproductive cell prior to<br \/>\n      fertilization) retrieved. Merck presented the results today at the 68<sup>th<\/sup><br \/>\n      Annual Meeting of the American Society for Reproductive Medicine.\n    <\/p>\n<p>\n      Merck remains on track to file a New Drug Application (NDA) for<br \/>\n      corifollitropin alfa with the U.S. Food and Drug Administration (FDA) in<br \/>\n      2013.\n    <\/p>\n<p>\n      &#8220;Infertility is an issue many couples in the U.S. face,&#8221; said Robert<br \/>\n      Boostanfar, M.D., study author, reproductive endocrinologist at HRC<br \/>\n      Fertility and clinical assistant professor at the Keck School of<br \/>\n      Medicine, Department of Obstetrics and Gynecology, University of<br \/>\n      Southern California. &#8220;If approved, corifollitropin alfa may provide<br \/>\n      clinicians with a different option for women undergoing controlled<br \/>\n      ovarian stimulation prior to IVF and ICSI.\u201d\n    <\/p>\n<p>\n      <b>Study Design<\/b>\n    <\/p>\n<p>\n      In the PURSUE trial, 1,390 women in the United States, aged 35-42 years,<br \/>\n      were evaluated in a randomized, double-blind, double-dummy, active<br \/>\n      controlled, non-inferiority trial. Participants, randomized and treated<br \/>\n      at 33 IVF centers in the United States, were selected based upon<br \/>\n      inclusion criteria which included women with an indication for<br \/>\n      controlled ovarian stimulation and IVF\/ICSI, who were between the ages<br \/>\n      of 35 and 42 with a body weight of \u2265 50 kg (\u2265 110 lbs) with a regular<br \/>\n      spontaneous menstrual cycle (cycle length 24-35 days). Key exclusion<br \/>\n      criteria included women with a recent history of\/or current endocrine<br \/>\n      abnormality, history of\/or current polycystic ovary syndrome, previous<br \/>\n      hyper-response or ovarian hyperstimulation syndrome (OHSS), previous<br \/>\n      low\/no ovarian response to FSH\/human menopausal gonadotropins (hMG),<br \/>\n      luteinizing hormone (LH) &gt; 12.0 IU\/L, and those who smoke or recently<br \/>\n      stopped smoking.\n    <\/p>\n<p>\n      The primary efficacy endpoint assessed the vital pregnancy rate, defined<br \/>\n      as the presence of at least one fetus with heart activity at least 35<br \/>\n      days or more after embryo transfer. The predefined non-inferiority<br \/>\n      margin was -8 percent. Secondary efficacy endpoints assessed the ongoing<br \/>\n      pregnancy rates (continued heart activity at least 10 weeks after embryo<br \/>\n      transfer, or live birth), and the number of oocytes retrieved. Other<br \/>\n      endpoints included a safety evaluation.\n    <\/p>\n<p>\n      During the first seven days of controlled ovarian stimulation, 694 women<br \/>\n      received a single injection of 150 mcg corifollitropin alfa and 696<br \/>\n      women were treated with seven daily injections of 300 IU rFSH. The mean<br \/>\n      age (standard deviation) for both treatment arms was 38.0 (2.2) years,<br \/>\n      and body weight (standard deviation) for the corifollitropin alfa and<br \/>\n      rFSH treatment arms were 67.8 kg (10.7) and 66.6 kg (10.8),<br \/>\n      respectively. Beginning on stimulation day 5, women in both treatment<br \/>\n      arms received daily ganirelix acetate injections (0.25 mg) (n= 692,<br \/>\n      99.7% and n= 694, 99.7%, respectively) until the time that recombinant<br \/>\n      human chorionic gonadotropin (hCG) was administered to trigger final<br \/>\n      oocyte maturation. When required, women in both treatment arms continued<br \/>\n      treatment from stimulation day 8 onwards with daily rFSH (maximally 300<br \/>\n      IU) until three follicles reached \u2265 17 mm. Three days after oocyte<br \/>\n      pick-up, two good quality embryos were to be transferred.\n    <\/p>\n<p>\n      <b>Efficacy Results<\/b>\n    <\/p>\n<p>\n      In the corifollitropin alfa treatment arm, the vital pregnancy rate per<br \/>\n      started cycle was comparable to that achieved in the rFSH treatment arm<br \/>\n      (n=166, 23.9% vs. n= 187, 26.9%, respectively). In line with the vital<br \/>\n      pregnancy rate, the observed ongoing pregnancy rate was 22.2 percent<br \/>\n      (n=154) per started cycle in the corifollitropin alfa treatment arm and<br \/>\n      24.0 percent (n=167) per started cycle in the rFSH treatment arm. The<br \/>\n      estimated differences and 95 percent confidence intervals were -3.0<br \/>\n      percent [-7.4 to 1.4] for the vital pregnancy rate and -1.9 percent<br \/>\n      [-6.1 to 2.3] for the ongoing pregnancy rate. The mean (standard<br \/>\n      deviation) number of recovered mature oocytes per started cycle was 10.7<br \/>\n      (7.2) and 10.3 (6.8), respectively, with a 95 percent confidence<br \/>\n      interval of 0.5 (-0.2 to 1.2).\n    <\/p>\n<p>\n      <b>Safety Profile<\/b>\n    <\/p>\n<p>\n      The overall rate of drug-related adverse events was 20.5 percent for<br \/>\n      woman receiving corifollitropin alfa and 18.5 percent for woman<br \/>\n      receiving rFSH. The overall incidence of serious adverse events (&gt;1.0%)<br \/>\n      in the corifollitropin alfa and rFSH treatment arms were 0.4 percent<br \/>\n      versus 2.6 percent, respectively. Treatment discontinuations due to<br \/>\n      adverse events (AEs) were 0.7 percent for women receiving<br \/>\n      corifollitropin alfa versus 0.9 percent for women receiving rFSH. The<br \/>\n      drug-related incidence of&nbsp;ovarian hyperstimulation syndrome (OHSS)&nbsp;in<br \/>\n      the corifollitropin alfa&nbsp;and rFSH treatment arms were 1.7 percent&nbsp;versus<br \/>\n      1.4 percent. The number of reported incidences of OHSS in the<br \/>\n      corifollitropin alfa and rFSH groups that required hospitalization were<br \/>\n      0.0 percent versus 0.3 percent, reported as a SAE were 0.0 percent<br \/>\n      versus 0.7 percent, or graded II (moderate) and\/or III (severe) were 0.7<br \/>\n      percent versus 1.4 percent, respectively. The most common drug-related<br \/>\n      AEs (&gt;1.0%) in women receiving corifollitropin alfa and rFSH,<br \/>\n      respectively, included headache (6.1% vs. 5.6%), pelvic discomfort (5.8%<br \/>\n      vs. 5.9%), nausea (3.9% vs. 2.4%), breast tenderness (2.6% vs. 1.1%),<br \/>\n      fatigue (1.9% vs. 2.0%), pelvic pain (1.6% vs. 1.6%), injection site<br \/>\n      pain (1.2% vs. 0.6%), and dizziness (0.6% vs. 1.1%).\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50451188&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=984dc6d758f7b511334662fe9fb43001\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that all of the expected synergies from the merger of Merck<br \/>\n      and Schering-Plough will not be realized, or will not be realized within<br \/>\n      the expected time period; the impact of pharmaceutical industry<br \/>\n      regulation and health care legislation in the United States and<br \/>\n      internationally; Merck\u2019s ability to accurately predict future market<br \/>\n      conditions; dependence on the effectiveness of Merck\u2019s patents and other<br \/>\n      protections for innovative products; and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50451188&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=e75805d4c2622700e30e41b174c61f79\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121023006538r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 908-423-5042<br \/>or<br \/>Tina        Grasso, 267-893-9783<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Phase III Study Presented at the Annual Meeting of the American Society for Reproductive Medicine Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from the PURSUE Phase III study of 1,390 women, aged 35-42 years, for corifollitropin alfa, the company&#8217;s investigational fertility treatment for controlled ovarian stimulation in women participating in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The study met its primary endpoint of achieving vital pregnancy rates with data revealing that a single injection of 150 mcg of corifollitropin alfa was non-inferior to seven daily injections of 300 IU recombinant follicle stimulating hormone (rFSH). The study also evaluated key secondary endpoints of ongoing pregnancy rates and the number of oocytes (the female reproductive cell prior to fertilization) retrieved. Merck presented the results today at the 68th Annual Meeting of the American Society for Reproductive Medicine.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289,56],"class_list":["post-742175","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation - Merck.com\" \/>\n<meta property=\"og:description\" content=\"New Phase III Study Presented at the Annual Meeting of the American Society for Reproductive Medicine Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from the PURSUE Phase III study of 1,390 women, aged 35-42 years, for corifollitropin alfa, the company&#039;s investigational fertility treatment for controlled ovarian stimulation in women participating in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The study met its primary endpoint of achieving vital pregnancy rates with data revealing that a single injection of 150 mcg of corifollitropin alfa was non-inferior to seven daily injections of 300 IU recombinant follicle stimulating hormone (rFSH). The study also evaluated key secondary endpoints of ongoing pregnancy rates and the number of oocytes (the female reproductive cell prior to fertilization) retrieved. Merck presented the results today at the 68th Annual Meeting of the American Society for Reproductive Medicine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121023006538r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\\\/\",\"name\":\"Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121023006538r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2012-10-23T13:15:00+00:00\",\"dateModified\":\"2023-03-22T04:04:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121023006538r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121023006538r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation - Merck.com","og_description":"New Phase III Study Presented at the Annual Meeting of the American Society for Reproductive Medicine Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from the PURSUE Phase III study of 1,390 women, aged 35-42 years, for corifollitropin alfa, the company's investigational fertility treatment for controlled ovarian stimulation in women participating in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The study met its primary endpoint of achieving vital pregnancy rates with data revealing that a single injection of 150 mcg of corifollitropin alfa was non-inferior to seven daily injections of 300 IU recombinant follicle stimulating hormone (rFSH). The study also evaluated key secondary endpoints of ongoing pregnancy rates and the number of oocytes (the female reproductive cell prior to fertilization) retrieved. Merck presented the results today at the 68th Annual Meeting of the American Society for Reproductive Medicine.","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:21+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121023006538r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/","name":"Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121023006538r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2012-10-23T13:15:00+00:00","dateModified":"2023-03-22T04:04:21+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121023006538r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121023006538r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-new-phase-iii-study-amongst-women-for-corifollitropin-alfa-an-investigational-fertility-treatment-for-controlled-ovarian-stimulation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9cb3f67d-0a76-4e4d-8f9e-9788a2b364a0","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Results-From-New-Phase-III-Study-Amongst-Women-for-Corifollitropin-Alfa-an-Investigational-Fertility-Treatment-for-Co-VZKEH.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742175\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742175"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}